Electronic components manufacturer CTS Corporation (NYSE: CTS) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 8% year on year to $143 million. The company’s full-year revenue guidance of $540 million at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $0.60 per share was 1.6% below analysts’ consensus estimates.
Is now the time to buy CTS? Find out in our full research report (it’s free for active Edge members).
CTS (CTS) Q3 CY2025 Highlights:
- Revenue: $143 million vs analyst estimates of $136.4 million (8% year-on-year growth, 4.8% beat)
- Adjusted EPS: $0.60 vs analyst expectations of $0.61 (1.6% miss)
- Adjusted EBITDA: $34.1 million vs analyst estimates of $32.12 million (23.9% margin, 6.2% beat)
- The company slightly lifted its revenue guidance for the full year to $540 million at the midpoint from $535 million
- Management lowered its full-year Adjusted EPS guidance to $2.23 at the midpoint, a 2.2% decrease
- Operating Margin: 14.6%, down from 16.8% in the same quarter last year
- Market Capitalization: $1.19 billion
StockStory’s Take
CTS faced a challenging Q3, with the market reacting negatively to its results despite revenue growth outpacing Wall Street’s expectations. Management attributed the underperformance to a mix of end market trends, including strong gains in medical, aerospace and defense, and industrial segments, offset by weaker transportation demand. CEO Kieran O’Sullivan highlighted that, “diversified sales for the quarter were 59% of overall company revenue,” reflecting an ongoing strategic focus. Margins were pressured by an adverse tax impact and a reserve increase related to an environmental claim.
Looking forward, CTS’s guidance reflects optimism around diversified end markets but caution over persistent headwinds. Management expects continued strength in therapeutic medical products and aerospace and defense, with SyQwest’s naval contract wins as a positive indicator. However, CFO Ashish Agrawal warned that recent U.S. tax legislation will continue to weigh on earnings, and transportation markets remain mixed. O’Sullivan noted, “we are closely monitoring the tariff and geopolitical environment,” emphasizing that cost management and supply chain agility will be critical for stability.
Key Insights from Management’s Remarks
Management attributed the quarter’s performance to robust growth in diversified end markets and the successful execution of its diversification strategy, even as transportation remained a drag and margin pressures persisted.
- Diversified end markets drive growth: CTS’s medical, aerospace and defense, and industrial segments saw double-digit sales increases, helping offset softness in transportation. Management pointed to strong bookings, especially in medical therapeutics and aerospace, as key contributors to revenue momentum.
- SyQwest momentum and naval contract: The SyQwest acquisition continues to deliver, with a $5 million sole-source naval defense contract and additional platform award opportunities expected in the next year. Management views SyQwest as pivotal for moving up the value chain from component supplier to subsystems provider in defense markets.
- Industrial recovery gains traction: CTS reported sequential and year-on-year growth in industrial end market sales, driven by OEM and distribution customers. Multiple wins in industrial printing, EMC, and heat pump sensing applications were highlighted as evidence of improving demand and execution.
- Transportation weakness and product updates: Transportation sales declined 7% year-over-year, primarily due to commercial vehicle softness. Nonetheless, CTS secured new accelerator module and braking sensor awards and launched COBROS technology for electric motor control, aiming to strengthen its position in vehicle electronics.
- Margin impacts from tax and reserves: Margins were negatively affected by changes in U.S. tax legislation and a $4.2 million reserve for an EPA reimbursement claim. The company also noted higher equity-based compensation, which together drove operating margin contraction despite gross margin improvement in diversified segments.
Drivers of Future Performance
CTS expects future performance to hinge on continued growth in diversified end markets, new defense wins, and careful margin management amid ongoing tax and transportation challenges.
- Diversified end market momentum: Management is optimistic about sustained growth in medical therapeutics, aerospace, and industrial segments, with strong pipelines and bookings expected to drive revenue. SyQwest’s naval defense backlog and further contract opportunities are seen as leading indicators for future performance.
- Transportation uncertainty and product launches: The outlook for transportation remains mixed, with ongoing softness in commercial vehicles but some positive signals in light vehicles and new product introductions such as braking sensors and COBROS technology. Management believes vehicle powertrain agnosticism will help mitigate volatility tied to electric and hybrid adoption rates.
- Margin headwinds and tax legislation: CFO Ashish Agrawal cautioned that adverse impacts from recent U.S. tax law changes will persist into next year, pressuring non-GAAP earnings. Operating expenses are also being monitored closely, particularly as reserves and compensation adjustments affect profitability.
Catalysts in Upcoming Quarters
Looking ahead, the StockStory team will watch (1) whether medical therapeutics and aerospace and defense bookings continue their current momentum, (2) signs of stabilization or recovery in transportation end markets, especially commercial vehicles, and (3) the ongoing impact of U.S. tax legislation and environmental reserves on margins. Progress on SyQwest’s contract pipeline and adoption of new vehicle electronics platforms will also be critical signposts.
CTS currently trades at $40.51, down from $42.41 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free for active Edge members).
Stocks That Trumped Tariffs
Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.
Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
